MEDICAL BREAKTHROUGHS
Untitled Page
Masimo, continued ...
However, conventional two-wavelength pulse oximeters are incapable of
measuring carboxyhemoglobin and methemoglobin levels, thus they cannot
provide clinicians with an accurate picture of true oxygenation status
in the presence of dyshemoglobins.
Masimo Rainbow SET-the
first-and-only technology that continuously and noninvasively measures
SpCO and SpMet, in addition to total hemoglobin (SpHb), oxygen content
(SpOC), PVI, oxyhemoglobin (SpO2), pulse rate and PI.
This
allows for faster and more accurate assessment of the patient's true
oxygenation, which may help to advance the care and management of
patients with sickle cell disease.
"This research not only
reinforces the clinical accuracy of SpCO and SpMet in assessing the
true oxygenation of patients, but also highlights the importance of
measuring these dyshemoglobins while managing and treating pediatric
patients with sickle cell disease," says Dr. Michael O’Reilly,
executive vice president of Medical Affairs for Masimo.
<< PREVIOUS PAGE
Related headlines
Huntington Beach’s Impact Medical rebrands as iTech Medical
AMDL of Tustin seals deal for cancer distribution
Costa Mesa's Oxygen Biotherapeutics inks deal with U.S. Navy
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCO may guage asthma severity in kids
Masimo, continued ...
However, conventional two-wavelength pulse oximeters are incapable of
measuring carboxyhemoglobin and methemoglobin levels, thus they cannot
provide clinicians with an accurate picture of true oxygenation status
in the presence of dyshemoglobins.Masimo Rainbow SET-the first-and-only technology that continuously and noninvasively measures SpCO and SpMet, in addition to total hemoglobin (SpHb), oxygen content (SpOC), PVI, oxyhemoglobin (SpO2), pulse rate and PI.
This allows for faster and more accurate assessment of the patient's true oxygenation, which may help to advance the care and management of patients with sickle cell disease.
"This research not only reinforces the clinical accuracy of SpCO and SpMet in assessing the true oxygenation of patients, but also highlights the importance of measuring these dyshemoglobins while managing and treating pediatric patients with sickle cell disease," says Dr. Michael O’Reilly, executive vice president of Medical Affairs for Masimo.
<< PREVIOUS PAGE
Related headlines
Huntington Beach’s Impact Medical rebrands as iTech Medical
AMDL of Tustin seals deal for cancer distribution
Costa Mesa's Oxygen Biotherapeutics inks deal with U.S. Navy
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCO may guage asthma severity in kids
